Significance of Thrombocytosis in Clinicopathologic Characteristics and Prognosis of Gastric Cancer

Abstract

Purpose: We aimed to study the relationship between thrombocytosis and clinical features of gastric cancerfocussing on platelet counts and gastric cancer progression through different TNM stages. Methods: According to the normal range of platelet count in our institution, 1,596 patients were divided to two groups: a thrombocytosis group (120 patients, >400×1000/μL) and a control group (1,476 patients, ≤400×1000/μL). Results: The incidence of thrombocytosis was 7.5%. Higher platelet counts were observed in patients with older age, larger tumor size, deeper invasion, lymph node metastasis, distant metastasis and advanced TNM stage. In multivariate logistic regression, tumor size, depth of tumor invasion, lymph node metastasis and TNM stage were independent risk factors for thrombocytosis of gastric cancer patients. On prognostic analysis, age, tumor size, tumor location, histologic type, depth of tumor invasion, lymph node metastasis, distant metastasis and TNM stage and platelet count were important factors. Tumor size, invasion depth, lymph node metastasis, TNM stage and the platelet count were independent prognostic factors. Conclusion: Thrombocytosis is associated with clinical features of gastric cancer patients and correlates with a poor prognosis.

The prognostic role of neutrophils to lymphocytes ratio and platelet count in gastric cancer: A meta-analysis

“…Four articles reported the link between preoperative platelet count and lymph node metastasis [6,11,26,27]. The incidence of lymph node metastasis was 1.62-fold higher in patients with elevated platelet count than in patients with normal platelet count (OR=1.62, 95% CI: 1.08-2.42, P=0.019) (Fig.…”

“…3A). Data for investigating the correlation between elevated platelet count and depth of tumor invasion (serosal invasion: positive (T3+T4) and negative (T1+T2) ) were available from 4 studies [6,11,26,27], the pooled analysis demonstrated that the incidence of serosal invasion (T3+T4) in patients with elevated platelet count was 2.09-fold higher than in patients with normal platelet count (OR=2.09, 95%CI 1.57-2.77, P <0.001) (Fig. 3B).…”

First Line Treatment for Advanced Gastroesophageal Cancer: Capecitabine Plus Oxaliplatin (CAPOX) versus Epirubicin, Oxaliplatin Plus Capecitabine (EOX)

“…On multivariate analysis for OS, higher platelet count >400000/cu mm conferred a poor prognosis. Poorer outcome with higher platelet count (>400000/cu mm) was also described by Li, et al [13]. In a multivariate prognostic factor analysis by Chau, et al in locally advanced/metastatic gastric cancer patients, ECOG performance status ≥2, high alkaline phosphatase level (>100 U/L) and site of metastasis (peritoneum, liver) had poor outcome [22].…”

“…Submit your Manuscript | www.austinpublishinggroup.com presented with increased platelet count and this was associated with poor prognosis [13].…”

The clinicopathological and prognostic role of thrombocytosis in patients with cancer: A meta-analysis

“…A total of 20 studies (7,(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30) that met the inclusion criteria were retrieved for analysis in the present study. The selection process of the included studies is presented in Fig.…”